Publication details
Hyperurikémie a dna u pacientů s DM 2. typu
| Title in English | Hyperuricemia and gout in patients with type 2 DM |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Diabetology news |
| MU Faculty or unit | |
| Citation | |
| Field | Other specializations of internal medicine |
| Keywords | diabetes mellitus type 2; gout; hyperuricemia; uric acid; cardiovascular risk; metabolic syndrome; therapy |
| Description | Gout represents a heterogeneous group of metabolic disease which is characterized by the formation and deposition of crystals of sodium urate deposit in various tissues. Hyperuricemia is the most important modifiable risk factor for the development gout. Hyperuricemia is also a significant risk for developing certain cardiovascular disease, type 2 diabetes mellitus, kidney disease and also for increased overall and cardiovascular mortality. Type 2 diabetes mellitus is a heterogeneous metabolic disease characterized by hyperglycemia. Combination of insulin deficiency and insulin resistance is the pathogenetic background of the disease. Elevated serum uric acid levels may be detected already in the early stages of glucose metabolism disorders. It is assumed that insulin resistance is a major risk factor for the development of metabolic syndrome, which is characterized by the presence of disorders of glucose metabolism, central type obesity, hypertension, dyslipidemia, but also hyperuricemia and prothrombotic state. Among these diseases and metabolic abnormalities there are a number of interdependent relationships that lead to an increase in the incidence of and contribute to increased total and cardiovascular mortality. Treating hyperuricemia leads not only to suppress the symptoms of gout, but can also contribute to reducing the risk of development of associated diseases, and reduce the total and cardiovascular mortality in patients with type 2 DM. |